The association of nonalcoholic fatty liver disease with bone mineral density in type 2 diabetes
Tóm tắt
We examined the association between nonalcoholic fatty liver disease and lumbar spine bone mineral density in individuals with and without type 2 diabetes. The lumbar BMD of 1088 subjects was measured using dual-energy X-ray absorptiometry (DXA). Liver fat content was quantified via B-mode ultrasound. Multivariable linear regression was used to study the association between NAFLD and lumbar BMD in participants with and without T2DM. The lumbar BMD in the T2DM group and the non-diabetes group was higher in the NAFLD group than in the non-NAFLD group (P < 0.001). Multivariate regression analysis in the T2DM group showed that after adjusting for confounders, the positive association between lumbar spine BMD and NAFLD remained (P = 0.027). In the non-diabetes group, after adjusting for confounders, the association between NAFLD and lumbar spine BMD disappeared. The relationship between nonalcoholic fatty liver disease and lumbar bone mineral density may differ in individuals with and without diabetes. The effect of nonalcoholic fatty liver disease on bone mineral density needs to be evaluated in different clinical contexts.
Tài liệu tham khảo
Lonardo A, Nascimbeni F, Mantovani A, Targher G. Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence? J Hepatol. 2018;68(2):335–52.
Emir M, Mikhailidis Dimitri P, Christos M. Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk. Metabolism. 2021;119:154770.
Muzurović E, Peng CC, Belanger MJ, Sanoudou D, Mikhailidis DP, Mantzoros CS. Nonalcoholic fatty liver disease and cardiovascular disease: a review of shared cardiometabolic risk factors. Hypertension. 2022. https://doi.org/10.1161/HYPERTENSIONAHA.122.17982.
Filip R, Radzki RP, Bieńko M. Novel insights into the relationship between nonalcoholic fatty liver disease and osteoporosis. Clin Interv Aging. 2018;13:1879–91.
Muzica CM, Sfarti C, Trifan A, Zenovia S, Cuciureanu T, Nastasa R, et al. Nonalcoholic fatty liver disease and type 2 diabetes mellitus: a bidirectional relationship. Can J Gastroenterol Hepatol. 2020;2020:6638306.
Lebeaupin C, Vallée D, Hazari Y, Hetz C, Chevet E, Bailly-Maitre B. Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease. J Hepatol. 2018;69(4):927–47.
Cusi K. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions. Diabetologia. 2016;59(6):1112–20.
Poggiogalle E, Donini LM, Lenzi A, Chiesa C, Pacifico L. Non-alcoholic fatty liver disease connections with fat-free tissues: A focus on bone and skeletal muscle. World J Gastroenterol. 2017;23(10):1747–57.
Ghodsi M, Larijani B, Keshtkar AA, Nasli-Esfahani E, Alatab S, Mohajeri-Tehrani MR. Mechanisms involved in altered bone metabolism in diabetes: a narrative review. J Diabetes Metab Disord. 2016;15:52.
Compston J. Type 2 diabetes mellitus and bone. J Intern Med. 2018;283(2):140–53.
Targher G, Lonardo A, Rossini M. Nonalcoholic fatty liver disease and decreased bone mineral density: is there a link? J Endocrinol Invest. 2015;38(8):817–25.
Chamberlain JJ, Herman WH, Leal S, Rhinehart AS, Shubrook JH, Skolnik N, et al. Pharmacologic therapy for type 2 diabetes: synopsis of the 2017 American Diabetes Association Standards of medical care in diabetes. Ann Intern Med. 2017;166(8):572–8.
Joy D, Thava VR, Scott BB. Diagnosis of fatty liver disease: is biopsy necessary? Eur J Gastroenterol Hepatol. 2003;15(5):539–43.
Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004;363(9403):157–63.
Lee SH, Yun JM, Kim SH, Seo YG, Min H, Chung E, et al. Association between bone mineral density and nonalcoholic fatty liver disease in Korean adults. J Endocrinol Invest. 2016;39(11):1329–36.
Kaya M, Işık D, Beştaş R, Evliyaoğ lu O, Akpolat V, Büyükbayram H, et al. Increased bone mineral density in patients with non-alcoholic steatohepatitis. World J Hepatol. 2013;5(11):627–34.
Ma C, Tonks KT, Center JR, Samocha-Bonet D, Greenfield JR. Complex interplay among adiposity, insulin resistance and bone health. Clinical obesity. 2018;8(2):131–9.
Reid IR. Fat and bone. Arch Biochem Biophys. 2010;503(1):20–7.
Kirchengast S, Peterson B, Hauser G, Knogler W. Body composition characteristics are associated with the bone density of the proximal femur end in middle- and old-aged women and men. Maturitas. 2001;39:133–45.
Cui Z, Xuan R, Yang Y. Serum fetuin A level is associated with nonalcoholic fatty liver disease in Chinese population. Oncotarget. 2017;8(63):107149–56.
Haukeland JW, Dahl TB, Yndestad A, Gladhaug IP, Løberg EM, Haaland T, et al. Fetuin A in nonalcoholic fatty liver disease: in vivo and in vitro studies. Eur J Endocrinol. 2012;166(3):503–10.
Sato M, Kamada Y, Takeda Y, Kida S, Ohara Y, Fujii H, et al. Fetuin-A negatively correlates with liver and vascular fibrosis in nonalcoholic fatty liver disease subjects. Liver Int. 2015;35(3):925–35.
Sun Y, Dai W, Liang Y, Yang P, Yang Q, Liang M, et al. Relationship between nonalcoholic fatty liver disease and bone mineral density in adolescents with obesity: a meta-analysis. DMSO. 2019;12:199–207.
Zillikens MC, Uitterlinden AG, van Leeuwen JP, Berends AL, Henneman P, van Dijk KW, Oostra BA, van Duijn CM, Pols HA, Rivadeneira F. The role of body mass index, insulin, and adiponectin in the relation between fat distribution and bone mineral density. Calcif Tissue Int. 2010;86:116–25.
Campos RM, de Piano A, da Silva PL, Carnier J, Sanches PL, Corgosinho FC, et al. The role of pro/anti-inflammatory adipokines on bone metabolism in NAFLD obese adolescents: effects of long-term interdisciplinary therapy. Endocrine. 2012;42(1):146–56.
Moon SS, Lee YS, Kim SW. Association of nonalcoholic fatty liver disease with low bone mass in postmenopausal women. Endocrine. 2012;42(2):423–9.
Carracher AM, Marathe PH, Close KL. International Diabetes Federation 2017. J Diabetes. 2018;10(5):353–6.
Lee SS, Park SH. Radiologic evaluation of nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20:7392–402.
Yaturu S. Diabetes and skeletal health. J Diabetes. 2009;1(4):246–54.
Blakytny R, Spraul M, Jude EB. Review: the diabetic bone: a cellular and molecular perspective. Int J Low Extrem Wounds. 2011;10(1):16–32.
Moyer-Mileur LJ, Slater H, Jordan KC, Murray MA. IGF-1 and IGF-binding proteins and bone mass, geometry, and strength: relation to metabolic control in adolescent girls with type 1 diabetes. J Bone Miner Res. 2008;23(12):1884–91.
Perseghin G, Ghosh S, Gerow K, Shulman GI. Metabolic defects in lean nondiabetic offspring of NIDDM parents: a cross-sectional study. Diabetes. 1997;46:1001–9.
Park SH, Kim BI, Yun JW, Kim JW, Park DI, Cho YK, Sung IK, Park CY, Sohn CI, Jeon WK, Kim H. Insulin resistance and C-reactive protein as independent risk factors for non-alcoholic fatty liver disease in nonobese. Asian men J Gastroenterol Hepatol. 2004;19:694–8.
Reid IR. Effects of vitamin D supplements on bone density. J Endocrinol Invest. 2015;38:91–4.
Ran C, Hui S, Xue-Fei R, Xiao-Yun C, Chun-Jun S, Ji-Ying W, Shen Q. Low bone mineral density in Chinese adults with nonalcoholic Fatty liver disease. Int J Endocrinol. 2013;2013:396545.
Bhatt SP, Nigam P, Misra A, Guleria R, Pasha MQ. Independent associations of low 25 hydroxy vitamin D and high parathyroid hormonal levels with nonalcoholic fatty liver disease in Asian Indians residing in north India. Atherosclerosis. 2013;230(1):157–63.